Skip to content
Screener

Alamar Biosciences ALMR GB — Revenue

Other financials

Income statement

See full
Revenue$26.0M+98.9%
Gross profit$14.5M+126%
Operating income-$12.3M-44.4%
Net income-$21.3M-178%
EPS (diluted)-$1.74-156%

Balance sheet

See full
Cash & equivalents$64.6M—
Total debt$30.6M—
Total equity-$178.1M—
Total assets$186.5M—

Cash flow

See full
Operating cash flow-$20.3M-55.7%
CapEx$600.0K+8.3%
Free cash flow-$20.9M-53.8%

Valuation

See full
Market cap$1.96B+37.6%
Enterprise value$1.93B—

Returns & leverage

See full
Debt / equity-0.2×—
Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.

Filed
May 8, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-213424
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
United States$14,905$9,469
Europe, Middle East and Africa (excluding United Kingdom)3,9721,422
United Kingdom3,4621,730
Asia-Pacific2,409450
Americas (excluding United States)1,28720
Total$26,035$13,091

Item 1. Financial Statements

FAQ

What is Alamar Biosciences's GB — revenue?
Alamar Biosciences (ALMR) reported GB — revenue of $3.46M in Q1 2026.

Ask your AI about Alamar Biosciences's gb — revenue.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude